Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

Serialization deadlines will shortly be upon us – but, rather than entering into a blind panic, consider the long term.

Even plastic used for biopharma manufacturing can be recycled, if we put our minds to it.

Thanks to the emergence of intensified and connected processes, the path to continuous biopharma manufacturing is open.

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

We must find ways to better help vaccine manufacturers to fight the flu – and this is why we developed a new challenge agent for H3N2.

As we meet increasing demand and satisfy trends towards self-administration in the injectables market, patient safety must remain the primary driver for innovation.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.